latest news releases from the newsroom
OXiGENE Reports Positive Phase 2 Interim Results in Platinum-Resistant Ovarian Cancer for Lead Vascular Disrupting Agent, ZYBRESTAT(tm)
WALTHAM, Mass., Oct. 27, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported positive interim results from an ongoing phase 2 study of ZYBRESTAT in patients with platinum-resistant ovarian cancer. Ten of 34 evaluable patients (29%) enrolled to date in the ongoing, single-arm, Simon two-stage design study evaluating the combination of ZYBRESTAT and chemotherapy (carboplatin and paclitaxel) had partial responses as measured by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria. An additional unconfirmed partial response was observed in a patient lost to follow up, and stable disease responses were observed in an additional nine patients. The combination regimen of ZYBRESTAT and chemotherapy was observed to be well tolerated.
NASDAQ OMX Group Hosts Its First Middle East Investor Conference in Dubai to Provide Issuers With Access to Gulf Investors
DUBAI, United Arab Emirates, Oct. 27, 2008 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today that it will host its first Middle East Investor Conference in Dubai on November 20, 2008. The event, to be held jointly with the Dubai International Financial Exchange (DIFX), will provide the Middle Eastern investor community with the opportunity to meet with and learn more about the strategies of leading listed companies, and provide companies with new exposure to the Gulf market. The conference will also feature a discussion of the DIFX's new equity derivatives initiative and the regional potential for exchange traded funds.
Nalco's Latest Water Treatment Innovations Highlighted At International Water Conference
NAPERVILLE, Ill., Oct. 26, 2008 (GLOBE NEWSWIRE) -- Nalco Company (NYSE:NLC), the global leader in water, energy, air and process technologies and services that deliver savings for customers and improve the environment, will make a series of presentations on latest advances in industrial water treatment as part of the International Water Conference (IWC) which opens today at the Crowne Plaza Riverwalk Hotel in San Antonio, Texas.
XOMA Presents Data On XOMA 052, An Anti-IL-1 Beta Antibody, in Rheumatoid Arthritis and Acute Gout Animal Models
BERKELEY, Calif., Oct. 25, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced that its poster titled "Efficacy Of XOMA 052 Anti-IL-1 Beta Antibody In The DBA/1 Mouse Collagen-Induced Arthritis Model" will be presented at the American College of Rheumatology 2008 Annual Conference, on Sunday, October 26 from 9:00 AM until 11:00 AM in Hall A. The poster also contains data demonstrating that XOMA 052 blocks inflammation in a mouse model of acute gout.
Lexicon Pharmaceuticals, Inc.
Lexicon Presents Phase 1 Clinical Trial Results for LX2931 At American College of Rheumatology Annual Meeting
THE WOODLANDS, Texas, Oct. 25, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, will be presenting results at the American College of Rheumatology annual meeting from its Phase 1 clinical trials of LX2931. Lexicon will also be presenting results from its preclinical research demonstrating activity of LX2931 in models of rheumatoid arthritis and inflammation. LX2931 is an orally-delivered, small molecule drug candidate that has successfully completed Phase 1 testing in normal volunteers. Lexicon is planning to progress LX2931 into a drug-drug interaction study in rheumatoid arthritis patients who are also taking methotrexate, a standard therapy.